source
- Merck's efinopegdutide shows strong MASH resolution in phase 2b trialMerck & Co. reported results from a phase 2b trial (MK-6024-013) evaluating efinopegdutide, a GLP-1 and glucagon receptor co-agonist, in patients with metabolic dysfunction-associated steatohepatit…
- Eli Lilly to pursue FDA approval for obesity drug in obstructive sleep apnea after positive Phase 3 trialEli Lilly announced that it will seek regulatory approval for its obesity medication as a treatment for obstructive sleep apnea, following a successful Phase 3 study. The trial showed positive res…